Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
08:00am, Tuesday, 05'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for AR
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
08:00am, Tuesday, 05'th May 2026
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals Precision approach targets patients who have a mutation in the PNPLA3 gene,
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
09:30am, Sunday, 03'rd May 2026
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 30'th Apr 2026
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
02:27pm, Tuesday, 28'th Apr 2026
Madrigal Pharmaceuticals, Inc. receives a Sell rating, citing high valuation and intensifying MASH competition despite Rezdiffra's initial commercial success. Rezdiffra achieved $958.4m in 2025 sales
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
02:38am, Monday, 27'th Apr 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has received an average rating of "Moderate Buy" from the seventeen ratings firms that are presently covering the company, Marketbeat.co
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
08:00am, Wednesday, 22'nd Apr 2026
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 21'st Apr 2026
CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
05:45pm, Thursday, 16'th Apr 2026
All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 07'th Apr 2026
CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the fourth quarter, according to the company in its most recent filing with the SEC. Th
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
03:17am, Monday, 30'th Mar 2026
Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the fourth quarter, according to the company in its most recent disclosure with t
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
10:06am, Friday, 27'th Mar 2026
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
05:24pm, Wednesday, 25'th Mar 2026
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review
01:16am, Friday, 20'th Mar 2026
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and SciSparc (NASDAQ: SPRC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companie
